Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
about
Systems biology of cisplatin resistance: past, present and futureFunctional DNA repair signature of cancer cell lines exposed to a set of cytotoxic anticancer drugs using a multiplexed enzymatic repair assay on biochipRad5 template switch pathway of DNA damage tolerance determines synergism between cisplatin and NSC109268 in Saccharomyces cerevisiaeEpimorphin-induced MET sensitizes ovarian cancer cells to platinumMolecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder CancerPrediction of chemo-response in serous ovarian cancerSuppression of annexin A11 in ovarian cancer: implications in chemoresistance.Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroidsLong noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells.Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeuticsCopper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cellsUpregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin.BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesSec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7AOvercoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell linesLow MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerA rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Bioengineering approaches to study multidrug resistance in tumor cells.BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinCytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells.Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.
P2860
Q50432263-4A5BE0B6-30E0-4016-A323-30142CFD1C0EQ54605971-36CB7DEB-01AC-4D12-B87C-EFF8F9565B3CQ54606559-02E1BED0-B9B2-4929-878E-BADF523D6D0BQ54937003-BD6A8B25-8A6B-4F2F-AB36-52E8BF410ED9Q54937004-D2F4A81D-371B-497D-ACF7-9F6BFB990712Q54937005-FAB29CE3-74B4-44E1-8262-EC574E34F857Q54937010-236FD7D7-A340-498F-9BCB-A39C425A74E8Q54937011-CBEB7CFF-4952-4A04-833D-DDD065BEAEDCQ54937013-3DE9D58C-76F7-470B-AEEA-8CF07F88F584Q54937014-9484C7B7-F4EC-4496-9613-8C647E4A92A6Q54947162-AA238EA6-8F1C-4DD4-87EF-4534C6F7CFACQ54947168-4AD8B6EB-90DB-4EAE-B029-9A1164E85D18
P1343
Q26863585-2D0542CD-1505-4ADD-A9B3-5B4A76171AD0Q28484673-7D42A2E9-53D5-421B-A052-4DA90A733497Q28534339-1C72B646-5C98-49C2-972C-69B7BCD2397FQ28536991-5AF5343E-C222-48E8-9D11-D5D3D0317F76Q28552735-609B0777-F5F3-4A3C-97F0-9DF1734FE592Q29248636-4CFB90C0-AF9B-4AC8-BB24-3625EFFFCFD6Q30487754-95D0478B-606D-49C2-8C0C-972DFB0678C7Q33321330-B489120B-F9A5-4C53-A0C3-1AD7FDFB0D45Q33671544-82EB7468-7EF1-4C9E-B206-6245A639F3F6Q33685268-FE825CA3-DC6E-4D37-AAD0-C1B24E16D39EQ33822719-722BA0D9-36EE-4BA9-89E2-BF5E9CF8E8BFQ34279411-2249ECD3-8F10-42DA-A4F2-86BFCAA095BBQ34458507-E2DCF659-22E8-47FA-8C70-959F4F0208C5Q34528724-7060492D-A6B3-445C-ACB3-04B9685D8E92Q34616645-EE52994A-181C-48CB-A241-1EC672D5DB9DQ35017209-7E90E135-1658-4501-8CD2-63F5809E05DBQ35041359-8827DBC2-DEAE-464D-AE41-2C344B87B577Q35051543-13FD5F7F-DE23-4B64-A33A-86F7C67B23B9Q35134877-C34141F4-4125-4553-B88F-EEE711EE852EQ35269409-EE8509F0-19CA-41AA-97A3-347713C40ADCQ35558646-4812A479-0630-488C-9B34-4B0B67B5E4FDQ35768666-51818E16-F168-4FC0-ACB7-F754C258EB3EQ35787316-313E4C64-A056-479F-8621-0E1FB59EEFB7Q35892810-F2D1985D-ED1D-4FFA-90EE-1F643BD1B57FQ36174748-E1EB6C80-0181-4874-B28F-58F806EAA5F4Q36294083-B16CAF25-AF3D-47E9-923D-6D2B0749E0A1Q36615007-89C12584-AF5E-438C-A86C-E6B0DCB21961Q36616527-37456067-7BC9-495D-92DD-7A9B62929D0CQ36648770-9B4A9A6E-0F8C-4733-A189-5B5CDFE803CEQ36670959-973CBEB6-3195-46F8-A931-AA307B1D1C10Q37200466-AF6DB208-4E74-4B5A-B7F0-A610C4364559Q37736567-2BE9860A-AA44-46E1-8C07-1F8AC9A9EAC7Q37851027-CAF64606-5DF7-4FF9-8002-684D4B80F369Q39392319-7F98F0C5-42F8-41BE-ACFE-A5DABE256104Q40836377-FEE5FD73-E759-47EC-8C63-7A96A89DAE60Q42544263-AD0C926F-4105-4057-A15E-B19B817E390CQ47129596-622CE957-CBBB-4C20-8926-360CE1582D05Q51734368-88517CC9-33D9-4D7A-814A-171550F59AF6
P2860
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@en
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@nl
type
label
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@en
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@nl
prefLabel
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@en
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@nl
P2093
P4510
P921
P1433
P1476
Increased platinum-DNA damage ...... man ovarian cancer cell lines.
@en
P2093
P304
P407
P577
1997-03-01T00:00:00Z